Trial reportHormones (Athens, Greece)2025
Efficacy of levocarnitine combined with tadalafil in treating oligozoospermia and asthenozoospermia: effects on serum sex hormones and sexual function.
Trial report in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Parathyroid disease, gut microbiome, biologic age, and more.Hormones (Athens, Greece) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the efficacy of combining levocarnitine with tadalafil in treating oligozoospermia and asthenozoospermia and to analyze its effects on serum sex hormone levels and sexual function.
methodsA total of 80 patients diagnosed with oligozoospermia or asthenozoospermia at our hospital between March 2023 and February 2024 were randomly divided into two groups, A and B, with 40 patients each. Group A received levocarnitine combined with tadalafil, while Group B was administered levocarnitine alone. Both groups continued the regimen for 3 months. Parameters such as serum sex hormones [testosterone (T), luteinizing hormone (LH), follicle-stimulating hormone (FSH)], sexual function [assessed via the International Index of Erectile Function (IIEF)], and semen quality [including semen volume, sperm concentration, sperm viability, and progressive motility (PR)] were measured pre- and post-treatment. Efficacy rates and adverse reactions were also recorded and compared between the groups.
resultsPost-treatment, both groups showed significant increases in serum T levels, all domains of IIEF scores (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction), semen volume, sperm concentration, sperm viability, and PR (p < 0.001). Group A demonstrated significantly better results than Group B in all these parameters (p < 0.05). Differences in LH and FSH levels between the groups after treatment were not statistically significant (p > 0.05). The total efficacy rate was significantly higher in Group A (87.50%) compared to Group B (67.50%) (p < 0.05). Adverse reactions occurred in 10% of Group A and 5% of Group B, with no significant difference between the groups (p > 0.05).
conclusionThe combination of levocarnitine and tadalafil shows significant efficacy and safety in treating oligozoospermia and asthenozoospermia, effectively enhancing serum testosterone levels, sexual function, and semen quality.
Indexed as
Identifiers
40928724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.